about
Smallpox vaccines for biodefense: need and feasibilityVaccines for preventing smallpoxThe evolution of poxvirus vaccinesHuman MonkeypoxSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesOrthopox Viruses: Infections in HumansMajor increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.Smallpox vaccine safety is dependent on T cells and not B cellsMicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacySafety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Serological responses in humans to the smallpox vaccine LC16m8.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Attenuation of Vaccinia VirusVaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccinationL1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccinesDisparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Enhancing poxvirus vectors vaccine immunogenicity.Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodiesVaccinia virus vaccines: past, present and future.Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.The strategic use of novel smallpox vaccines in the post-eradication world.Replicating poxviruses for human cancer therapy.Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity.Challenges and Achievements in Prevention and Treatment of Smallpox.Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8.
P2860
Q22305942-EFB4F4A9-0537-4FBB-96EC-6F89ACD99A61Q24244234-71748A9A-D275-439D-8965-D4349AFB24EFQ26995905-CDE2D826-0C34-4556-B6F1-576987A1410EQ27023061-81115736-3FB5-42A1-BE95-4514D4624A0EQ27325586-8AEF3F0F-F004-4D41-9492-24B464A6ADD1Q28742218-99745E08-636C-4874-84CF-BF22D949E471Q34136736-143B24F3-01DF-4403-8E31-9CFA1B4EAD2CQ34289866-5BCA2DE7-7D6F-4C1D-9180-4A3F2D670342Q34743303-660D21C6-0532-4E96-9C02-AD6896160347Q35086717-88FD834D-FA8A-4883-9665-E1FB0E0C7087Q35557123-BDB4AD5E-123C-4526-96CE-A755AAEBBBD1Q35571248-5E7A26D5-8F85-4747-B2D9-DE15995E5C2CQ35826728-16877237-8AC9-4B91-9917-BA613742340BQ35945094-E5F47AEE-ED49-4F82-BD69-D1A9074F3B89Q36391900-40DC8BB6-C3F9-4D80-92B6-C7E3003E076DQ36475175-11867282-98E8-4A65-9161-D5CAEA60E87CQ36797094-BDB622A9-A369-4574-BA2C-CC06AF2BE7A6Q36798711-D388258B-8AA9-47E7-9E1D-984DA6FEAEECQ36845650-DC4D9789-504D-4112-A4D5-8F1083A7FFE9Q36978452-152E5AD3-F5D1-4A12-ACB4-E3CB835CEDFBQ37066691-F7F93265-94E5-4A56-B511-68B5BB346570Q37343595-7EE94F03-9757-4286-A65A-B39F5895FC87Q37349246-E05FFDFE-2E74-458F-AE36-5DAEB2EB72DEQ37461110-013CCC97-B635-46C1-8FB9-0956D8FEE29DQ37524022-BBB4CF74-5149-4B7D-B1E3-29DC84984C83Q37791160-3DF6D77C-5908-46C1-9AB2-BD829E2DC5DBQ37909421-703915CA-B43F-4543-8B63-55A6D1861CC7Q38407351-4F1588F7-5A53-4BA0-A395-89C72D8F167AQ40083001-6020EEC9-4040-46B8-A370-188F21BE8F59Q45388494-5977C58D-92A3-4357-881E-9B77DC0958FFQ47547852-9B00277A-FFB7-4D00-9E06-C98EDC4A5980Q52688303-BD8B901E-F448-4536-937F-581F314E9050
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
LC16m8: an attenuated smallpox vaccine.
@ast
LC16m8: an attenuated smallpox vaccine.
@en
type
label
LC16m8: an attenuated smallpox vaccine.
@ast
LC16m8: an attenuated smallpox vaccine.
@en
prefLabel
LC16m8: an attenuated smallpox vaccine.
@ast
LC16m8: an attenuated smallpox vaccine.
@en
P2093
P1433
P1476
LC16m8: an attenuated smallpox vaccine.
@en
P2093
Cyril Empig
David V Jobes
Fiona Cameron
Julie Kenner
Marc Gurwith
P304
P356
10.1016/J.VACCINE.2006.03.087
P407
P577
2006-04-21T00:00:00Z